IP Verse

Process For Preparing High Purity Degree Larotrectinib - EP4294810

The patent EP4294810 was granted to Olon on Oct 16, 2024. The application was originally filed on Feb 18, 2022 under application number EP22712444A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4294810

OLON
Application Number
EP22712444A
Filing Date
Feb 18, 2022
Status
Granted And Under Opposition
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCORPIOJul 16, 2025SAGITTARIUSADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2016077841
INTERNATIONAL-SEARCH-REPORTWO2019220352
OPPOSITIONWO2010048314
OPPOSITIONWO2016077841

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- SCOTT LESLEY J., "Larotrectinib: First Global Approval", NZ, vol. 79, no. 2, doi:10.1007/s40265-018-1044-x, ISSN 0012-6667, (20190201), pages 201 - 206, DRUGS, URL: http://link.springer.com/content/pdf/10.1007/s40265-018-1044-x.pdf, XP055843384 [A] 1-4 * the whole document *
OPPOSITION- Anonymous, "Assessment report - VITRAKVI - International non-proprietary name: larotrectinib", EMA; Procedure No. EMEA/H/C/004919/0000; EMA/CHMP/469135/2019 Committee for Medicinal Products for Human Use (CHMP), (20190725), XP093301102
OPPOSITION- Anonymous, "ICH HARMONISED GUIDELINE - IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R6)", INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE, (20161020), INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE, URL: https://database.ich.org/sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf, XP093301104
OPPOSITION- Anonymous, "ICH Harmonised Tripartite Guideline - Impurities In New Drug Substances Q3A(R2)", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20061025), INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , XP093157689
OPPOSITION- Kavitapu Dasameswararao, Maruthapillai Arthanareeswari, Tamilselvi M., "Identification and characterization of unknown degradation product of larotrectinib sulphate", Materials Today: Proceedings, Elsevier, NL, NL , (20210101), vol. 40, doi:10.1016/j.matpr.2020.06.526, ISSN 2214-7853, pages S172 - S179, XP093301105

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents